Thursday, September 24, 2015

Exclusive Interview with Dr. Ian Tomlinson of GlaxoSmithKline

As Senior Vice President and Head of Biopharmaceuticals R&D and Head of Biopharmaceuticals R&D and Worldwide Business Development (WWBD) at GlaxoSmithKline, Dr. Tomlinson combines the resources and development expertise of a large pharmaceutical company, with the entrepreneurial spirit of a smaller biotech organization, bringing early research, late-stage biopharm development and manufacturing expertise into one organization. He served as the Chief Scientific Officer and Executive Vice President of Domantis Inc., and Domantis Limited. Dr. Tomlinson co-founded Domantis Limited in 2000.

In this interview, listen to his views on antibody therapeutic development, shaped by his background both in large pharma and smaller biotech.


Ian Tomlinson is one of the scientific advisory board members and organizers of the Antibody Engineering & Therapeutics conference scheduled for December 7-10, 2015 in San Diego.

Download the event agenda now.

Register now with the code D15172BLOG and save $400!


Share this article with your social network, just click below to share now!


1 comment :

vivaan Edwardd said...

Thank you for such a fantastic blog. Where else could anyone get that kind of info written in such a perfect way? I have a presentation that I am presently working on, and I have been on the lookout for such information.
latest technologies in computer

Post a Comment